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Abstract Tocilizumab (TCZ) and tumour necrosis factor in-
hibitors (TNFi) are recommended for the treatment of rheu-
matoid arthritis (RA) in patients with inadequate response (IR)
to prior disease-modifying antirheumatic drugs (DMARDs).
This retrospective analysis assessed the efficacy of TCZ and
TNFi, alone or in combination with DMARDs, in 1603
patients with IR to previous treatment with either DMARDs
(DMARD-IR) and/or TNFi (TNFi-IR), initiating treatment
with TCZ or a TNFi, managed in routine clinical practice.
Patients were grouped according to treatment history and
treatment initiated: DMARD-IR patients initiating treatment
with TCZ +DMARD (DMARD-IRTCZ) or TNFi + DMARD
(DMARD-IR TNFi), DMARD-IR and/or TNFi-IR patients
initiating treatment with TCZ monotherapy (TCZ mono) or
TNFi monotherapy (TNFi mono), and TNFi-IR patients initi-
ating treatment with TCZ + DMARD (TNFi-IRTCZ) or TNFi
+ DMARD (TNFi-IR TNFi). Patients initiating treatment with
TCZ generally had more severe disease and longer disease
duration compared with the corresponding TNFi group. Sig-
nificantly more patients achieved remission (DAS28 ESR
<2.6) in the TCZ groups compared with corresponding TNFi
groups (DMARD-IR, TCZ 44.0 % vs. TNFi 29.6 %; mono-
therapy, TCZ 37.2 % vs. TNFi 30.2 %; TNF-IR, TCZ 41.3 %
vs. TNFi 19.2 %; p<0.001 for all comparisons). More patients
achieved moderate–good responses (EULAR criteria) in the
TCZ treatment groups (79–85 %) compared with TNFi treat-
ment groups (65–81 %). Patient-reported outcomes showed
greater improvements in TCZ compared with TNFi groups.
In patients with inadequate response to DMARDs and/or
TNFi treated in routine clinical practice, TCZ in combination
with DMARDs or as monotherapy resulted in significantly
more patients achieving remission and more marked improve-
ments in patient-reported outcomes compared with TNF
inhibitors.
Keywords DMARDs . Patient-reported outcomes .
Remission . Rheumatoid arthritis . Routine practice .
Tocilizumab . Tumour necrosis factor inhibitors
M. Backhaus (*)
Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische
Immunologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1,
10117 Berlin, Germany
e-mail: backhaus@park-klinik.com
J. Kaufmann
Praxis Dr. med Jörg Kaufmann, Ludwigsfelde, Germany
e-mail: dr.joerg.kaufmann@web.de
C. Richter
Internistisch-rheumatologische Schwerpunktpraxis,
Stuttgart, Germany
e-mail: richter@t-online.de
S. Wassenberg
Fachkrankenhaus Ratingen - Rheumatologische Klinik,
Rheumazentrum Ratingen, Ratingen, Germany
e-mail: wassenberg@clinic.de
A.<E. Roske
Roche Pharma AG, Grenzach-Wyhlen, Germany
e-mail: anne-eve.roske@roche.com
P. Hellmann
Chugai Pharma, Frankfurt, Germany
e-mail: p.hellmann@chugaipharma.de
M. Gaubitz
Akademie für Manuelle Therapie an der WWUMünster,
Interdisziplinäre Diagnostik und Therapie, Münster, Germany
e-mail: gaubitz@uni-muenster.de
Clin Rheumatol (2015) 34:673–681
DOI 10.1007/s10067-015-2879-0
Introduction
Rheumatoid arthritis (RA) is a common chronic inflam-
matory disease associated with progressive joint destruc-
tion, pain, fatigue and disability. Current treatments target
the inflammatory response using disease-modifying anti-
rheumatic drugs (DMARDs) and biological agents, in
combination or as monotherapy. Five classes of biologics
with differing modes of action are currently used in the
treatment of RA: tumour necrosis factor inhibitors (TNFi)
(adalimumab, certolizumab, etanercept, golimumab and
infliximab), an interleukin (IL)-1 receptor antagonist
(anakinra), a selective T-cell costimulatory modulator
(abatacept), a chimeric anti-CD20 monoclonal antibody
(rituximab) and a humanised anti–IL-6 receptor antibody
(tocilizumab (TCZ)). Treatment guidelines recommend
DMARDs (initially methotrexate [MTX]) as immediate
first-line therapy in patients with RA, followed by com-
bination therapy with conventional DMARDs, or with bi-
ological agents in combination with DMARDs, should
patients fail to achieve remission or low disease activity
on DMARDs alone [1, 2]. Monotherapy with biologics is
not generally recommended for all agents in current
guidelines, although in German guidelines, TCZ is recom-
mended as monotherapy particularly in patients with in-
tolerance to MTX or when the continuation of MTX ther-
apy is considered inappropriate for other reasons [3]. The
majority of available data on biologics in RA have been
from studies of TNFis, and although shown to be more
effective in combination with MTX than MTX alone,
TNFi monotherapy was also shown to be less effective
than combination therapy [4–8]. In more recent studies,
TCZ has been shown to be effective both in combination
with DMARDs and also as monotherapy in patients who
had previously had an inadequate response to DMARDs
(DMARD-IR) [9–13] or to TNF inhibitors (TNFi-IR)
[14–16]. Most recently, the large Phase IV ADACTA trial
demonstrated superior efficacy for monotherapy with TCZ
as compared to monotherapy with the TNFi adalimumab
in patients who were intolerant to, or unsuitable for, treat-
ment with methotrexate [17]. However, such suitably
powered randomised clinical head-to-head trials for bio-
logics in RA are rare. Due to strict inclusion and exclu-
sion criteria, a randomised trial might not reflect clinical
practice; therefore, retrospective analyses of data from
registries and chart-based analyses of patients treated in
routine clinical practice may help guide decision-making
for clinicians managing RA patients.
The current study therefore aimed to assess the efficacy
of TCZ as compared with TNF inhibitors, alone or in com-
bination with DMARDs, in patients with an inadequate re-
sponse to prior DMARDs and/or TNFi managed in routine
clinical practice.
Materials and methods
This was a retrospective analysis of data from patients with
RA managed in centres (office-based practices and clinics)
throughout Germany. Centres that had treated at least three
suitable patients in each specified TCZ and TNFi treatment
group within the time period specified below were eligible to
take part in the study. Patients who had inadequate response
(IR) to previous treatment with either DMARDs (DMARD-
IR) or with a TNFi (TNF-IR), or a combination of both, and
who subsequently initiated treatment with either TCZ or a
TNFi between 1 January 2010 and 31 December 2011 were
eligible for inclusion. No other inclusion or exclusion criteria
were specified. Collection of patient data was performed be-
tween January and May 2012. All data were fully
anonymised; therefore, no patient consent was required for
this analysis. Due to the non-interventional and anonymised
nature of this analysis, no ethical approval of this study was
required according to German drug law.
Data for eligible patients were collected via online case
report forms (CRFs). For quality assurance, automatic online
queries were generated in the CRF where data input appeared
to be anomalous. Baseline demographics data, including sex,
age, employment status, comorbidities, RA duration and treat-
ment history at initiation of TCZ or the reference TNF inhib-
itor were collected. In addition, the following data were col-
lected at baseline (defined as initiation of TCZ or reference
TNFi) and week 12 of treatment where available: laboratory
data including rheumatoid factor (RF) and anti-cyclic
citrullinated peptide antibody (ACCP), haemoglobin, C-
reactive protein (CRP) and erythrocyte sedimentation rate
(ESR); and clinical assessments including swollen joint count
(SJC) and tender joint count (TJC), patient- and physician-
reported global health assessment by visual analogue scale
(VAS), morning stiffness (minutes as assessed by patient)
and corticosteroid requirement. Disease activity score 28 joint
(DAS28), clinical disease activity score (CDAI) and simpli-
fied disease activity score (SDAI) were calculated automati-
cally. The occurrence of adverse events (AEs) was recorded in
a simplified manner as having been experienced or not expe-
rienced; no detailed description of the type or nature of AEs
was collected. All collected data were analysed as observed;
missing data were treated as treatment failures.
Outcomes
The main outcome parameters were remission, defined as
DAS28 (ESR) <2.6, and European League Against Rheuma-
tism (EULAR) response, 3 months after initiation of treatment
with TNFi or TCZ.
Patients were divided into six groups based on their treat-
ment history and treatment initiated during the study period:
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1. DMARD-IR patients initiating treatment with TCZ +
DMARD (DMARD-IR TCZ)
2. DMARD-IR patients initiating treatment with a TNFi +
DMARD (DMARD-IR TNFi)
3. DMARD-IR and/or TNFi-IR patients initiating treatment
with TCZ monotherapy (TCZ mono)
4. DMARD-IR and/or TNFi-IR patients initiating treatment
with TNFi monotherapy (TNFi mono)
5. TNFi-IR patients initiating treatment with TCZ +DMARD
(TNFi-IR TCZ)
6. TNFi-IR patients initiating treatment with TNFi +DMARD
(TNFi-IR TNFi)
Statistics
Summary statistics (mean, median, standard deviation, 25th
percentile, 75th percentile, minimum, maximum, number of
values) or frequencies and proportions were assessed for all
collected parameters. Independent two-sample t test with
Levene’s test for equality of variances and t test for equality
of means was used. Significance level was p<0.05.
Results
In total, 1603 patients from 70 centres were included in the
study. Of these, 95 % were from community-based practices
and 5% fromRA clinics. Baseline demographics are shown in
Table 1. TNFis initiated during the observational period were
as follows: adalimumab (39.5 %), etanercept (29.0 %),
certolizumab pegol (14.7 %), golimumab (12.9 %) and
infliximab (3.8 %).
The TCZ and TNFi groups were comparable with regard to
age and gender distribution, and disease duration. However,
patients initiating treatment with TCZ generally had more se-
vere disease than those in the corresponding TNFi group (e.g.
higher SJC, TJC, morning stiffness, DAS28, and patient and
physician VAS scores). Significantly more patients in the
DMARD-IR TCZ group and the TCZ mono group had
DAS28 (ESR) >5.1 at baseline comparedwith the correspond-
ing TNFi groups (65 vs. 55 %, and 65 vs. 54 %, respectively;
p<0.001). In addition, the proportion of patients with invalid-
ity retirement due to RAwas higher in the TCZ groups. TCZ
patients in both the monotherapy and TNFi-IR group had been
more extensively pre-treated compared with patients initiating
a TNFi and had received significantly more prior treatment
with biologicals (Table 1).
The number and nature of comorbidities were generally
similar between TCZ and TNFi groups, with the exception
of the monotherapy groups, where patients initiating TCZ
monotherapy had a higher proportion of comorbidities com-
pared with those initiating TNFi monotherapy (Table 2).
The reasons for the use of monotherapy given most com-
monly by clinicians were (multiple reasons could be given)
the following: efficacy of monotherapy (TCZ 56 %, TNFi
44 %), intolerance to prior therapy (TCZ 48 %, TNFi 52 %),
compliance issues (TCZ 52 %, TNFi 48 %), contraindications
(hepatic, TCZ 40 %, TNFi 60 %; renal, TCZ 11 %, TNFi
89 %), de-escalation of therapy e.g. scaling down from com-
bination to monotherapy (TCZ 42 %, TNFi 58 %).
Efficacy
The proportion of patients achieving remission (DAS28 ESR
<2.6) was significantly higher in the TCZ groups compared
with corresponding TNFi groups (Fig. 1a). Overall, the pro-
portion of patients who achieved remission at week 12 was
similar between the different TNFis and was higher in patients
treated with TCZ (Fig. 1b).
The proportion of patients achieving moderate-to-good or
good responses according to EULAR criteria was higher in
the TCZ treatment groups compared with the corresponding
TNFi treatment groups (Fig. 2). In agreement with this, the
proportion of patients who failed to respond to therapy was
higher in the TNFi treatment groups compared with the cor-
responding TCZ treatment groups (Fig. 2). Non-response led
to treatment discontinuation in 4.4 % of patients treated with
TCZ and 12.2 % of patients treated with TNFi. It should be
noted that achieving a ‘moderate response’ by EULAR criteria
was sufficient for some patients to enter remission.
The proportion of patients achieving low disease activity
(DAS28 ESR ≤3.2) at week 12 was significantly greater in the
TCZ treatment groups comparedwith the corresponding TNFi
groups (DMARD-IRTCZ 64 %; DMARD TNFi 50 %; mono
TCZ 51 %; mono TNFi 45 %; TNF-IR TCZ 60 %; TNF-IR
TNFi 36 %; p≤0.01 for all comparisons).
Patients treated with TCZ also showed greater improve-
ments in CDAI score at week 12 of treatment vs. baseline
compared with those treated with TNFi, and this reached sta-
tistical significance in the monotherapy and TNFi-IR groups
(Fig. 3). There was no significant difference between TCZ and
TNFi arms with regard to change in SDAI with the exception
of the monotherapy arms where patients treated with TCZ
showed significantly greater improvements (data not shown).
The majority of patients included in the study were able to
reduce their steroid use over the 12-week treatment period
(80 % in the TCZ groups and 70 % in the TNFi groups; p=
non-significant). Overall, the mean reduction in steroid reduc-
tion was not significantly different between groups, with the
exception of the TCZ and TNFi monotherapy groups, where
mean dose reduction was higher in the TCZ group (mean
change [dose equivalent, mg/day]: DMARD-IR TCZ −2.5;
DMARD TNFi −2.4; mono TCZ −2.5; mono TNFi −0.6;
TNF-IR TCZ −1.6; TNF-IR TNFi −2.0).
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Patient-reported outcomes improved in all treatment
groups (Fig. 4a–c). Overall, there were greater improvements
in morning stiffness, patient global health and pain with TCZ
compared with TNFi in all groups indicating the better reduc-
tion of disease activity by TCZ.
Safety and tolerability
Overall, 4.8 % of patients in the TCZ groups and 3.2 % of
patients in the TNFi groups experienced treatment-associated
adverse events (AEs). No serious AEs were reported. Rates of
treatment discontinuation due to AEs were low in all groups
(overall rate 3 % in the TCZ groups vs. 1 % in the TNFi
groups). Although further details of AEs as reported to Roche
as part of post-marketing safety surveillance were available,
no such data were available for TNFi; therefore, no further
comparisons are possible.
Discussion
In this large cohort of patients with inadequate response to
DMARDs and/or TNFi managed in routine clinical practice,
patients treated with TCZ alone or in combination with
DMARDs had significantly higher rates of remission
(DAS28<2.6) compared with patients treated with similar
Table 1 Baseline demographics
DMARD-IR DMARD-IR and/or TNF-IR TNF-IR
TCZ + DMARD
(n=250)
TNFi + DMARD
(n=286)
TCZ mono
(n=288)
TNFi mono
(n=272)
TCZ + DMARD
(n=259)
TNFi + DMARD
(n=248)
Female/male, % 72/28 71/29 83/17 82/18 76/24 75/25
Age, years±SD 57±12 55±12 58±14 58±13 56±12 55±12
RA duration, years±SD 9±8 9±8 12±9 11±9 12.5±10 11±8
Employment status, %
Full employment 80.6 85.2 63.9 76.9 58.3 72.6
Invalidity retirement due to RA 17.5 11.3 28.6 19.8 38.8 22.6
Previous therapya
Methotrexateb, % 76 74 38 40 74 72
Leflunomideb, % 29 32 25 30 17 23
Number DMARDs 2.2 2.2 2.7** 2.4** 2.5 2.4
Number Biologicals 0 0 1.3*** 0.5*** 1.6*** 1.2***
Corticosteroid equivalent, mg/day 7.7 8.4 8.3 7.9 7.5 7.9
RF/ACPA positive, % 55/55 53/49 59/54 58/51 55/51 56/48
Number co-morbidities 1.88 1.84 2.02 1.86 1.80 1.94
Clinical parameters
SJC 7.2±4.9 6.9±4.7 6.8±4.8* 5.6±4.2* 6.3±4.2 5.9±4.9
TJC 9.0±5.6 8.7±5.9 9.1±6.2* 7.7±5.3* 8.0±5.4 7.7±5.6
ESR, mm/h 36±24* 31±22* 36±25 33±23 37±24** 33±22**
CRP, mg/L 25±36*** 17±24*** 24±33 16±21 23±30** 18±22**
Morning stiffness (minutes) 69±49 66±50 68±50* 60±47* 74±56** 61±48**
VAS PGH 61±21 55±23 63±20 55±22 63±19 59±20
VAS PGA 58±19 54±21 61±18* 53±19* 60±17 56±18
DAS28 (ESR) 5.4±1.3 5.2±1.2 5.4±1.3*** 5.1±1.2*** 5.3±1.2 5.1±1.3
DAS28 (CRP) 5.0±1.1* 4.8±1.1* 5.0±1.1*** 4.6±1.1*** 4.9±1.0 4.7±1.2
CDAI 30±13 28±12 31±12*** 25±11*** 29±11* 27±13*
SDAI 28±11 26±11 28±11*** 24±10*** 27±10 25±12
ACPA anti-cyclic citrullinated peptide antibody, CDAI clinical disease activity score,CRP C-reactive protein,DAS28 disease activity score 28 joint, ESR
erythrocyte sedimentation rate, PGA physician global assessment, PGH patient global health, RF rheumatoid factor, SDAI simplified disease activity
score, SJC swollen joint count, TJC tender joint count, VAS visual analogue scale
*p<0.05; **p<0.01; ***p<0.001
aMultiple answers possible
b In the 6 weeks prior to baseline
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regimens using TNFi. Treatment with TCZ was also associat-
ed with higher rates of good or moderate EULAR response
and lower rate of non-response compared with TNFi and
significantly greater improvements in CDAI. Improvements
in patient-reported outcomes such as morning stiffness and
pain also tended to be greater in patients treated with TCZ
compared with those treated with TNFi.
The greater efficacy of TCZ compared with TNFi was ap-
parent despite the fact that patients in the TCZ groups gener-
ally had more severe disease and had been more intensively
pre-treated compared with those in the corresponding TNFi
groups. Overall, our data suggests that patients in the TCZ
treatment groups had a history of greater disease impairment,
with fewer patients in full-time employment and more patients
having entered invalidity retirement due to RA. This may be a
reflection of EULAR treatment guidelines in place at the time
of the study which recommend that TNFi should be the first
biologic DMARD used (in combination with MTX) for pa-
tients who fail to respond to conventional DMARDs; current
guidelines do not specify [2]. Loss of work productivity oc-
curs early in the course of the disease and contributes greatly
to the overall costs of RA [9, 17]. In a Swedish study, work
disability made up the largest cost of RA, exceeding the costs
associated with treatment [18]. Achievement of disease remis-
sion has been shown to be associated with lower number of
Fig. 1 DAS28 remission at week
12. DAS28 (ESR)<2.6. DAS28
disease activity score 28 joint,
DMARD disease-modifying anti-
rheumatic drugs, ESR erythrocyte
sedimentation rate, IR insufficient
response, TCZ tocilizumab, TNFi
tumour necrosis factor inhibitor
Table 2 Comorbidities (% of patients)
DMARD-IR Mono TNF-IR
TCZ TNFi TCZ TNFi TCZ TNFi
Osteoporosis 33.2 34.3 36.5 36.0 31.7 33.1
Hypertension 28.4 33.2 38.9 31.2 30.1 38.7
Obesity 22.0 19.9 19.1 17.6 25.5 23.4
Anaemia 18.8 17.6 20.8 14.6 15.6 12.6
Lipid metabolism disorder 12.8 9.4 10.4 7.7 8.9 6.9
Diabetes mellitus 11.2 8.0 13.5 8.8 11.2 11.7
COPD/asthma 8.0 5.6 5.9 8.1 6.5 8.4
Depression (diagnosed) 3.6 4.9 5.2 3.3 3.5 5.2
Depression (suspected) 6.0 3.5 3.8 2.9 3.5 2.0
Coronary heart disease 3.2 4.6 2.8 3.3 5.0 2.8
Hypothyroidism 4.8 2.4 4.2 5.1 4.2 4.0
Hyperthyroidism 3.2 2.4 1.7 1.5 2.7 4.4
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days lost from work due to sick leave and permanent work
disability [19]. Available data suggest a decrease in work dis-
ability in patients with RA over recent years which may be
associated with more active treatment strategies and more
specifically the introduction of biologics [20–22].
Although achieving disease control and thereby prevention
of structural damage is the primary goal when treating RA,
other aspects of the disease may be more important to the
patient. Morning stiffness and pain have been shown to be
closely related to functional disability [23] and to have adverse
effects on quality of life, ability to work and the need for early
retirement due to RA [24, 25]. Improvements in these param-
eters are important as these debilitating symptoms can occur
even in patients with apparently well-controlled RA [26]. In
our cohort, there was an improvement in patient-reported out-
comes including morning stiffness, global health and pain
after 12 weeks of treatment in all patient groups. Change from
baseline was numerically and generally significantly greater in
TCZ-treated patients. These patients were generally more
symptomatic at baseline compared with the corresponding
TNFi treatment group, which potentially might have contrib-
uted to the greater overall change seen. Patients with RA have
Fig. 2 EULAR-Response at week 12 by EULAR criteria. n.s. not significant, DMARD disease-modifying anti-rheumatic drugs, EULAR
European League Against Rheumatism, IR insufficient response, TCZ tocilizumab, TNF-i tumour necrosis factor inhibitor
Fig. 3 Mean change in CDAI (95 % CI) at week 12 vs. baseline by treatment group. n.s. not significant, CDAI clinical disease activity score,
DMARD disease-modifying anti-rheumatic drugs, IR insufficient response, TCZ tocilizumab, TNFi tumour necrosis factor inhibitor
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been shown to have raised serum concentrations of pro-
inflammatory cytokines compared with normal controls
which correlate with disease activity. However, while levels
of TNF do not change significantly during the overnight pe-
riod, patients with active RA have been found to have elevated
levels of IL-6 during the early morning, which are linked to
morning stiffness and pain [27]. The potential ability of TCZ
to block this circadian increase in IL-6 may contribute to its
better efficacy in reducing these symptoms compared with
TNFi seen in our study. However, as morning stiffness is
related to a range of features other than IL-6 levels, such as
disease activity level and general health [28], other factors
may also contribute. It would be of interest to investigate other
patient-reported outcomes. However, the collection of data on
measures such as the Health Assessment Questionnaire
(HAQ) and the Funktionsfragebogen Hannover (FFbH) is
not routinely collected in Germany and was performed at the
discretion of clinician in the current study. Although a limited
number of these data were available, they were too small to
allow statistical comparison.
As this study was not a controlled head-to-head comparison
of TCZ and TNFis, comparative data should be treated with
caution. Although several studies have compared biologics
with different modes of action in patients with RA, to date, only
two trials in DMARD-IR patients have included an adequately
powered head-to-head comparison. The AMPLE trial com-
pared abatacept, a selective T-cell costimulatory modulator
and the TNFi adalimumab, both in combination with a stable
dose of methotrexate, and found no difference in efficacy be-
tween the two agents based on clinical, functional and radio-
graphic outcomes [29]. In contrast, in the ADACTA trial which
compared TCZ monotherapy with adalimumab monotherapy
in MTX-ineligible patients with severe RA, TCZ was found to
be more effective than the comparator, with significantly
Fig. 4 Patient-reported outcomes
at baseline and week 12 by
treatment group: aMorning
stiffness, b VAS patient global
health (100 units) and c VAS Pain
(100 units). n.s. not significant,
DMARD disease-modifying anti-
rheumatic drugs, IR insufficient
response, PGH patient global
health, TCZ tocilizumab, TNFi
tumour necrosis factor inhibitor,
VAS visual analogue scale
Clin Rheumatol (2015) 34:673–681 679
greater improvements in DAS28 (−3.3 vs. −1.8, respectively;
p<0.0001), and significantly more patients achieving remis-
sion (DAS<2.6: 39.9 vs. 10.5 %, respectively; p<0.0001), as
well as EULAR good or moderate (77.9 vs. 54.9%; p<0.0001)
and good responses (51.5 vs. 19.8 %; p<0.0001) [17]. The
rates of remission and response in the current observational
study were somewhat higher than those obtained in ADACTA,
possibly reflecting the fact that patients in the latter trial had
more severe RA overall than those in our trial (DAS28 6.7 in
ADACTAvs. around 5.3 in the current study) and the patients
treated with monotherapy in CONSENS were DMARD and/or
TNF-IR. Although the use of biologics as monotherapy is not
generally recommended by guidelines, studies suggest that it
still is widely used in routine clinical practice [23, 30]. A recent
‘real-world’ study found that TCZ monotherapy was more
effective in terms of reducing DAS28 and was better tolerated
compared with TNFi in 254 RA patients treated in 30 centres in
Germany [30]. Our study therefore supports and adds to the
available data on the use and efficacy of TCZ and TNFi as
monotherapy in routine practice and also provides additional
data on real-world efficacy of combination therapy in both
DMARD-IR and TNFi-IR patients.
One of the main advantages of the current study is the en-
rolment of a large number of patients from an extensive range
of clinical practices. Despite obvious limitations compared with
prospective studies, retrospective studies provide an important
source of information on the efficacy of treatment under real-
life conditions. The simple inclusion criteria used in the current
study ensured that a wide range of RA patients were included,
more closely reflecting typical patients encountered in daily
practice as compared with those in clinical trials, which have
highly restrictive inclusion and exclusion criteria.
This study has the usual limitations related to its retro-
spective, uncontrolled nature. Although participating cen-
tres were encouraged to include all eligible patients on their
lists, selection bias cannot be excluded. Choice of therapy
was at the discretion of the clinician; therefore, selection
bias for treatment choice also cannot be ruled out. Only data
actually recorded were available for inclusion. Not all pa-
tients had results for all parameters at each time point, and
this was particularly notable for some parameters which are
not routinely performed in day-to-day practice in Germany.
Missing data may therefore potentially have affected over-
all results. Detailed data on adverse events (AEs) were not
recorded; although the numbers of AEs reported were sim-
ilar between TCZ- and TNFi-treated patients, no informa-
tion on the nature or severity of AEs was available. Finally,
we selected the study period to reflect EULAR guidelines
which recommend the main efficacy assessment 12 weeks
after therapy initiation or adjustment. Data are therefore
relatively short-term, and longer-term studies are required
to confirm if the improvements seen at 12 weeks are
sustained over long-term treatment.
In summary, in DMARD-IR and TNFi-IR patients treated in
routine clinical practice, TCZ in combinationwith DMARDs or
as monotherapy resulted in significantly more patients achiev-
ing remission compared with TNF inhibitors, although TCZ-
treated patients had more severe disease of longer duration at
baseline. In addition, significantly greater improvements were
seen in patient-reported outcomes such asmorning stiffness and
pain in TCZ-treated patients. Fewer patients treated with TCZ
discontinued treatment due to non-response.
Acknowledgments We thank all participants in the study. We thank Dr.
Barbara Schäfer who provided editorial assistance funded by Roche
Pharma AG, Grenzach-Wyhlen, Germany. The study was supported by
Roche Pharma AG, who contributed to the study design, data collection
and analysis. The decision to submit the manuscript for publication was
made solely by the authors.
Conflict of interest MB has received research grants and speaker fees
from Roche Pharma and Chugai Pharmaceuticals. JK has received re-
search grants, investigator fees and speaker fees from Roche Pharma
and Chugai Pharmaceuticals. CR has received honoraria for participation
in Roche Pharma advisory boards. SW received investigator fees from
Roche Pharma. A-ER is an employee of Roche Pharma.PH is an employ-
ee of Chugai Pharmaceuticals Germany.
MG received investigator fees from Roche Pharma. In addition, MB
has received research grants fromAbbVie, BMS,MSD, Pfizer and speak-
er fees from AbbVie, BMS, MSD and Pfizer. JK received speaker fees
from Abbott, Pfizer and UCB and has participated in clinical trials from
Abbott and Pfizer. SW has received unconditional research grants of less
than 5000 € from Roche Pharma and Chugai Pharmaceuticals and Pfizer,
and consultancy fees and honoraria of less than 5000 € per year from
Roche Pharma, Chugai Pharmaceuticals, Abbott, Pfizer, UCB and MSD.
MG received honoraria for consultations or presentations from AbbVie,
Amgen, BMS, Chugai, Hexal, Merck, MSD, Mundipharma, Pfizer,
Roche, SOBI and UCB.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M,
Baerwald C et al (2014) German guidelines for the sequential med-
ical treatment of rheumatoid arthritis with traditional and biologic
disease-modifying antirheumatic drugs. Rheumatol Int 4:1–9
2. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P,
Gaujoux-Viala C et al (2010) EULAR recommendations for the man-
agement of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs. Ann Rheum Dis 69:964–975
3. Krüger K,Wollenhaupt J, Albrecht K,Alten R, BackhausM, Baerwald
C et al (2012) German 2012 guidelines for the sequential medical
treatment of rheumatoid arthritis. Adapted EULAR recommendations
and updated treatment algorithm. Z Rheumatol 71:592–603
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J,
Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J,
Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and
Methotrexate with Radiographic Patient Outcomes) Study
Investigators (2004) Therapeutic effect of the combination of
680 Clin Rheumatol (2015) 34:673–681
etanercept and methotrexate compared with each treatment alone in
patients with rheumatoid arthritis: double-blind randomised con-
trolled trial. Lancet 363:675–681
5. Breedveld FC,WeismanMH, Kavanaugh AF, Cohen SB, Pavelka K,
van Vollenhoven R, Sharp J, Perez JL, Spencer-GreenGT (2006) The
PREMIER study: a multicenter, randomized, double-blind clinical
trial of combination therapy with adalimumab plus methotrexate ver-
sus methotrexate alone or adalimumab alone in patients with early,
aggressive rheumatoid arthritis who had not had previous methotrex-
ate treatment. Arthritis Rheum 54:26–37
6. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH,
Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver
AL, Markenson J, Finck BK (2000) A comparison of etanercept
and methotrexate in patients with early rheumatoid arthritis. N Engl
J Med 343:1586–1593
7. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T,
Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T (2010)
Etanercept (ETN) with methotrexate (MTX) is better than ETN
monotherapy in patients with active rheumatoid arthritis despite
MTX therapy: a randomized trial. Mod Rheumatol 20:531–538
8. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C,
Bolosiu H, Melo-Gomes J, Tornero-Molina J,Wajdula J, Pedersen R,
Fatenejad S, TEMPO Study Investigators (2006) Comparison of
etanercept and methotrexate, alone and combined, in the treatment
of rheumatoid arthritis: two-year clinical and radiographic results
from the TEMPO study, a double-blind, randomized trial. Arthritis
Rheum 54:1063–1074
9. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM,
Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C,
Huizinga TW (2013) Adding tocilizumab or switching to tocilizumab
monotherapy in methotrexate inadequate responders: 24-week symp-
tomatic and structural results of a 2-year randomised controlled strate-
gy trial in rheumatoid arthritis (ACT-RAY). Ann RheumDis 72:43–50
10. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA,
Alecock E,Woodworth T,Gomez-Reino JJ (2008) Interleukin-6 receptor
inhibition with tocilizumab reduces disease activity in rheumatoid arthri-
tis with inadequate response to disease-modifying antirheumatic drugs:
the tocilizumab in combination with traditional disease-modifying anti-
rheumatic drug therapy study. Arthritis Rheum 58:2968–2980
11. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky
J, Alecock E, Woodworth T, Alten R, OPTION Investigators (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients
with rheumatoid arthritis (OPTION study): a double-blind, placebo-
controlled, randomised trial. Lancet 371:987–997
12. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ,
Siri DA, Tomsic M, Alecock E,Woodworth T, Genovese MC (2010)
Comparison of tocilizumab monotherapy versus methotrexate mono-
therapy in patients with moderate to severe rheumatoid arthritis: the
AMBITION study. Ann Rheum Dis 69:88–96
13. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM,
Vernon E, Ambs P, Fleischmann R (2011) Tocilizumab inhibits struc-
tural joint damage in rheumatoid arthritis patients with inadequate
responses to methotrexate: results from the double-blind treatment
phase of a randomized placebo-controlled trial of tocilizumab safety
and prevention of structural joint damage at one year. Arthritis
Rheum 63:609–621
14. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R,
Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibi-
tion with tocilizumab improves treatment outcomes in patients with
rheumatoid arthritis refractory to anti-tumour necrosis factor biolog-
icals: results from a 24-week multicentre randomised placebo-
controlled trial. Ann Rheum Dis 67:1516–1523
15. Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima
H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T,
Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y
(2010) Clinical evaluation of tocilizumab for patients with active
rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in
combination with methotrexate. Mod Rheumatol 20:343–352
16. Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport
J, Singh N, Lepley D, Genovese MC (2013) Tocilizumab as
monotherapy or in combination with nonbiologic disease-
modifying antirheumatic drugs: twenty-four-week results of an
open-label, clinical practice study. Arthritis Care Res (Hoboken)
65:362–371
17. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R,
Pavelka K, Klearman M, Musselman D, Agarwal S, Green J,
Kavanaugh A, ADACTA Study Investigators (2013) Tocilizumab
monotherapy versus adalimumabmonotherapy for treatment of rheu-
matoid arthritis (ADACTA): a randomised, double-blind, controlled
phase 4 trial. Lancet 381:1541–1550
18. Hallert E, Husberg M, Skogh T (2006) Costs and course of disease
and function in early rheumatoid arthritis: a 3-year follow-up (the
Swedish TIRA project). Rheumatology (Oxford) 45:325–331
19. Hallert E, HusbergM, Skogh T (2011) 28-Joint count disease activity
score at 3 months after diagnosis of early rheumatoid arthritis is
strongly associated with direct and indirect costs over the following
4 years: the Swedish TIRA project. Rheumatology (Oxford) 50:
1259–1267
20. ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A (2012) The
effect of biological agents on work participation in rheumatoid arthri-
tis patients: a systematic review. Ann Rheum Dis 71:161–171
21. Hallert E, Husberg M, Bernfort L (2012) The incidence of permanent
work disability in patients with rheumatoid arthritis in Sweden 1990–
2010: before and after introduction of biologic agents. Rheumatology
51:338–346
22. Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T,
Korpela M, Möttönen T, Puolakka K (2013) Decline in work disabil-
ity caused by early rheumatoid arthritis: results from a nationwide
Finnish register, 2000–8. Ann Rheum Dis 72:672–677
23. Yazici Y, Shi N, John A (2008) Utilization of biologic agents in
rheumatoid arthritis in the United States: analysis of prescribing pat-
terns in 16,752 newly diagnosed patients and patients new to biologic
therapy. Bull NYU Hosp Jt Dis 66:77–85
24. da Silva JA, Phillips S, Buttgereit F (2011) Impact of impaired morn-
ing function on the lives and well-being of patients with rheumatoid
arthritis. Scand J Rheumatol 125:6–11
25. Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A (2008) Morning
stiffness and its influence on early retirement in patients with recent
onset rheumatoid arthritis. Rheumatology (Oxford) 47:980–984
26. Kirwan JR, Buttgereit F (2012) Symptom control with low-dose glu-
cocorticoid therapy for rheumatoid arthritis. Rheumatology (Oxford)
51:14–20
27. Perry MG, Kirwan JR, Jessop DS, Hunt LP (2009) Overnight varia-
tions in cortisol, interleukin 6, tumour necrosis factor alpha and other
cytokines in people with rheumatoid arthritis. Ann Rheum Dis 68:
63–68
28. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen
TM, Huisman M, Kallikorm R, Muller R, Liveborn M, Oding R,
Luchikhina E, Naranjo A, Rexhepi S, Taylor P, Tlustochowich W,
Tsirogianni A, Sokka T, QUEST-RA Group (2009) Re-evaluation of
the role of duration of morning stiffness in the assessment of rheu-
matoid arthritis activity. J Rheumatol 36:2435–2442
29. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G,
Elegbe A, Maldonado M, Fleischmann R (2014) Head-to-head com-
parison of subcutaneous abatacept versus adalimumab for rheuma-
toid arthritis: two-year efficacy and safety findings from AMPLE
trial. Ann Rheum Dis 73:86–94
30. Kaufmann J, Feist E, Roske AE, Schmidt WA (2013) Monotherapy
with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid
arthritis: efficacy, treatment satisfaction, and persistence in routine
clinical practice. Clin Rheumatol 32:1347–1355
Clin Rheumatol (2015) 34:673–681 681
